In this issue:
Talquetamab superior to current treatments in triple-class-exposed RRMM
Lower risk of infection with GPRC5D vs BCMA targeted bispecific antibodies
Infections in patients receiving teclistamab for RRMM
Outcomes after first-line quadruplet induction therapy failure
Novel individualised risk classifier in myeloma
Ide-cel CAR T-cell therapy feasible in patients with renal impairment
KarMMa-3: superior health-related quality of life with ide-cel
Salvage T-cell redirection therapy may be an option after allograft
Intentified pre-transplant conditioning with carfilzomib
TTK inhibitor OSU-13 is a potential therapeutic strategy for myeloma
Please login below to download this issue (PDF)